Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion.

Sonam Ansel,Robert Rulach, Nicola Trotter,Nicola Steele

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2022）

引用 5|浏览0

暂无评分

摘要

Patients with previous AI diseases tolerate treatment well, and there is a non-significant trend for improved outcomes in this group. Patients who complete the course of pembrolizumab have significantly better survival outcomes than those who do not.

查看译文

关键词

Lung cancer,NSCLC,autoimmunity,immunotherapy,pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要